Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Xiaochaihu decoction (MXD) is a traditional Chinese medicine (TCM) herbal formula derived from the classical Xiaochaihu decoction. It is composed of the original ingredients—primarily Bupleurum chinense DC.—with additional herbs such as Phyllanthus urinaria, Atractylodes macrocephala (largehead atractylodes rhizome), Poria cocos, Paeonia lactiflora (white peony root), and Schisandra chinensis (Fructus Schisandrae)[3]. MXD has been widely used in Asia for thousands of years to treat various chronic diseases. Modern clinical studies have demonstrated its efficacy in treating gastroesophageal reflux disease (GERD), where it shows similar or superior effects compared to proton pump inhibitors in improving esophageal motility and reducing symptom recurrence[1][5][7]. It has also been studied for persistent depressive disorder when combined with mirtazapine[4], and for chronic hepatitis B due to its hepatoprotective and antiviral properties mediated partly through modulation of the JAK2/STAT3 signaling pathway[3]. The mechanism of action involves multi-target regulation including anti-inflammatory effects, immune modulation, hepatoprotection, and possible antiviral activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified xiaochaihu decoction.